SABCS15: Promising phase 1 results lead to phase 2 for ONT-380 in HER2+ breast cancer
Results of an ongoing phase 1b clinical trial presented at the 2015 San Antonio Breast Cancer Symposium show promise of the experimental anti-cancer agent ONT-380 against metastatic HER2+ breast...